Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AL-335, Odalasvir, and Simeprevir for Chronic Hepatitis C has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• AL-335 (AL-335)
• Odalasvir (odalasvir)
• Simeprevir (simeprevir)

Snippet

Sponsor: Alios Biopharma Inc. | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2019-07-16